Citadel Advisors’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Citadel Advisors’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,024	Closed	-$74.7K	–	15658
2023 Q4	$74.7K	Buy	+10,024	New	+$65.3K	﹤0.01%	11307
2023 Q3	–	Sell	-2,592	Closed	-$18.7K	–	15350
2023 Q2	$18.7K	Buy	+2,592	New	+$18.8K	﹤0.01%	12788
2023 Q1	–	Sell	-6,337	Closed	-$42.3K	–	15724
2022 Q4	$42.3K	Buy	+6,337	New	+$55.6K	﹤0.01%	12338
2022 Q3	–	Sell	-2,816	Closed	-$34K	–	13848
2022 Q2	$34K	Buy	+2,816	New	+$44.5K	﹤0.01%	12160
2022 Q1	–	Sell	-2,314	Closed	-$139K	–	14816
2021 Q4	$139K	Buy	2,314 +571	+33%	+$42.7K	﹤0.01%	12372
2021 Q3	$163K	Buy	+1,743	New	+$232K	﹤0.01%	12264

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's TLIS Position: Q1 2024 in Review

Citadel Advisors sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q1 2024, closing a stake of 10,024 shares — an estimated $74.7K sold.

Citadel Advisors first reported a position in TLIS in Q3 2021 and held it in 6 quarters. The position peaked at $163K in Q3 2021. 18 funds tracked by Wall St. Rank hold TLIS as of Q1 2024.

Citadel Advisors reported no remaining Talis Biomedical Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 10,024 Talis Biomedical Corporation Common Stock shares in Q1 2024, an estimated $74.7K.
Citadel Advisors first reported a position in Talis Biomedical Corporation Common Stock in Q3 2021 and held it in 6 quarters.
Citadel Advisors's Talis Biomedical Corporation Common Stock position peaked at $163K in Q3 2021.
18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.